World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
101
Citations
91484
World Ranking
7771
National Ranking
4049

Overview

Omid Hamid is affiliated with Cedars-Sinai Medical Center in the United States and has contributed extensively to the field of medicine, focusing primarily on oncology. Their work encompasses subfields such as oncology, immunology, molecular biology, pulmonary and respiratory medicine, and ophthalmology.

Their research spans several main topics, including:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Melanoma and MAPK Pathways
  • Cutaneous Melanoma Detection and Management
  • Ocular Oncology and Treatments
  • Cancer Research and Treatments

Omid Hamid has published multiple papers in notable journals. Some recent works include:

  • "Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma," 2021, New England Journal of Medicine
  • "Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma," 2021, Journal of Clinical Oncology
  • "Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma," 2020, Clinical Cancer Research
  • "Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study," 2022, Journal for ImmunoTherapy of Cancer
  • "Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma," 2023, New England Journal of Medicine

The frequent coauthors collaborating with Omid Hamid include:

  • Inderjit Mehmi
  • Paolo A. Ascierto
  • Karl D. Lewis
  • Jeffrey S. Weber
  • Alexander N. Shoushtari

The primary publication venues for Omid Hamid's work are:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts
  • Cancer Research
  • Journal for ImmunoTherapy of Cancer

Omid Hamid's research focus integrates cancer immunotherapy and treatments related to melanoma, including ocular and cutaneous types. Their work on checkpoint inhibitors, tumor-infiltrating lymphocyte therapies, and bispecific fusion proteins addresses treatment approaches in metastatic melanoma cases.

Best Publications

  • Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

    Julie R. Brahmer;Scott S. Tykodi;Scott S. Tykodi;Laura Q.M. Chow;Wen Jen Hwu

  • Pembrolizumab for the treatment of non-small cell lung cancer

    Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl

  • Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

  • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    Roy S. Herbst;Jean Charles Soria;Marcin Kowanetz;Gregg D. Fine

  • Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi

  • Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

    Jedd D. Wolchok;Axel Hoos;Steven O'Day;Jeffrey S. Weber

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

    Dirk Schadendorf;F. Stephen Hodi;Caroline Robert;Jeffrey S. Weber

  • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

    Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer

  • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean Jacques Grob;Reinhard Dummer

  • Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

    Howard L. Kaufman;Jeffery Russell;Omid Hamid;Shailender Bhatia

  • Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    Jacob Schachter;Antoni Ribas;Georgina V. Long;Ana Arance

  • Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

    Hussein A. Tawbi;Peter A. Forsyth;Alain Algazi;Omid Hamid

  • Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

    Antoni Ribas;Omid Hamid;Adil Daud;F. Stephen Hodi

  • Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial

    Kim Margolin;Marc S Ernstoff;Omid Hamid;Donald Lawrence

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

    Gerald S Falchook;Georgina V Long;Georgina V Long;Razelle Kurzrock;Kevin B Kim

  • Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    Caroline Robert;Antoni Ribas;Jacob Schachter;Ana Arance

Frequent Co-Authors

Adil Daud
Adil Daud University of California, San Francisco
Caroline Robert
Caroline Robert University of Paris-Saclay
Antoni Ribas
Antoni Ribas University of California, Los Angeles
F. Stephen Hodi
F. Stephen Hodi Harvard University
Richard F. Kefford
Richard F. Kefford Macquarie University
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Jeffrey S. Weber
Jeffrey S. Weber New York University
Igor Puzanov
Igor Puzanov Roswell Park Cancer Institute
Georgina V. Long
Georgina V. Long University of Sydney
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, a range of related online degrees can open doors to diverse career pathways in healthcare. For those interested in nutrition and wellness, online nutrition degrees equip students with foundational knowledge for becoming dietitians, health coaches, or community educators.

Aspiring healthcare leaders may consider pursuing top cahme accredited mha programs. These programs focus on healthcare administration and management, offering flexible online formats for working professionals who want to oversee hospital operations or healthcare systems.

Registered Nurses (RNs) seeking career advancement have options like online rn to bsn programs without clinicals. These programs provide streamlined learning experiences, ideal for those whose schedules or circumstances make in-person clinicals challenging.

For nurses advancing toward leadership or specialist roles, the shortest msn to dnp program offers a fast-track to earn a Doctor of Nursing Practice degree. This can significantly accelerate your ability to effect change in clinical practice and healthcare policy.

Exploring these flexible, online pathways can help you build a rewarding healthcare career that fits your interests and lifestyle.

Best Scientists Citing Omid Hamid

Trending Scientists